These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 32801334)
21. Voigt E; Wallenburg M; Wollenzien H; Thompson E; Kumar K; Feiner J; McNally M; Friesen H; Mukherjee M; Afeworki Y; Kareta MS Mol Cancer Res; 2021 Dec; 19(12):2015-2025. PubMed ID: 34593608 [TBL] [Abstract][Full Text] [Related]
22. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China. Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456 [TBL] [Abstract][Full Text] [Related]
23. SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. Redin E; Sridhar H; Zhan YA; Pereira Mello B; Zhong H; Durani V; Sabet A; Manoj P; Linkov I; Qiu J; Koche RP; de Stanchina E; Astorkia M; Betel D; Quintanal-Villalonga Á; Rudin CM J Hematol Oncol; 2024 Jul; 17(1):58. PubMed ID: 39080761 [TBL] [Abstract][Full Text] [Related]
24. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer. Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118 [TBL] [Abstract][Full Text] [Related]
25. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Augustyn A; Borromeo M; Wang T; Fujimoto J; Shao C; Dospoy PD; Lee V; Tan C; Sullivan JP; Larsen JE; Girard L; Behrens C; Wistuba II; Xie Y; Cobb MH; Gazdar AF; Johnson JE; Minna JD Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14788-93. PubMed ID: 25267614 [TBL] [Abstract][Full Text] [Related]
26. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers. Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680 [TBL] [Abstract][Full Text] [Related]
27. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. Ng J; Cai L; Girard L; Prall OWJ; Rajan N; Khoo C; Batrouney A; Byrne DJ; Boyd DK; Kersbergen AJ; Christie M; Minna JD; Burr ML; Sutherland KD Clin Cancer Res; 2024 May; 30(9):1846-1858. PubMed ID: 38180245 [TBL] [Abstract][Full Text] [Related]
28. Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer. Wei J; Liu L; Guo Y; Zhang J; Wang X; Dong J; Xing P; Ying J; Yang L; Li J Thorac Cancer; 2021 Jan; 12(1):40-47. PubMed ID: 33191657 [TBL] [Abstract][Full Text] [Related]
29. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor. Kim G; Kim M; Nam EJ; Lee JY; Park E Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832 [TBL] [Abstract][Full Text] [Related]
30. An integrative transcriptome analysis reveals a functional role for thyroid transcription factor-1 in small cell lung cancer. Horie M; Miyashita N; Mattsson JSM; Mikami Y; Sandelin M; Brunnström H; Micke P; Nagase T; Saito A J Pathol; 2018 Oct; 246(2):154-165. PubMed ID: 29876935 [TBL] [Abstract][Full Text] [Related]
31. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702). Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H; Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386 [TBL] [Abstract][Full Text] [Related]
32. ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation. Alam SK; Wang L; Ren Y; Hernandez CE; Kosari F; Roden AC; Yang R; Hoeppner LH Br J Cancer; 2020 Sep; 123(5):819-832. PubMed ID: 32499571 [TBL] [Abstract][Full Text] [Related]
33. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin. Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040 [TBL] [Abstract][Full Text] [Related]
34. Molecular features and evolutionary trajectory of ASCL1 Zhang X; Wang H; Liu W; Xiao Z; Ma Z; Zhang Z; Gong W; Chen J; Liu Z Br J Cancer; 2023 Mar; 128(5):748-759. PubMed ID: 36517551 [TBL] [Abstract][Full Text] [Related]
35. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer. Tsuboyama N; Wang R; Szczepanski AP; Chen H; Zhao Z; Shi L; Wang L Oncogene; 2022 Apr; 41(15):2152-2162. PubMed ID: 35194152 [TBL] [Abstract][Full Text] [Related]